Please use this identifier to cite or link to this item:
Title: Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
Austin Authors: John, Thomas ;Bowden, Jeffrey J;Clarke, Stephen;Fox, Stephen B;Garrett, Kerryn;Horwood, Keith;Karapetis, Christos S
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Flinders Medical Centre and Flinders University, South Australia, Australia
Royal North Shore Hospital, New South Wales, Australia
Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Victoria, Australia
Australian Clinical Labs, Subiaco, West Australia, Australia
Icon Cancer Care, South Brisbane, Queensland, Australia
Issue Date: Aug-2017 2017-07-12
Publication information: Asia-Pacific Journal of Clinical Oncology 2017; 13(4): 296-303
Abstract: First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring a sensitizing mutation in the EGFR gene. Unfortunately, resistance to these therapies often occurs within 10 months of commencing treatment and is mostly commonly due to the development of the EGFR T790M mutation. Treatment with the third-generation EGFR TKI, osimertinib can prolong progression free survival in patients with the T790M mutation, so it is important to determine the resistance mechanism in order to plan ongoing therapeutic strategies. Here we review the evidence and make recommendations for the timing of T790M mutation testing, the most appropriate specimens to test and the available testing methods in patients progressing during treatment with first line EGFR TKIs for NSCLC.
DOI: 10.1111/ajco.12699
PubMed URL:
Type: Journal Article
Subjects: EGFR TKI
T790M mutation
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.